Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Exclusion Criteria

• •Patients who have received any prior chemotherapy, radiotherapy or investigational agents for pancreatic cancer.
• •Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
• •Has received prior therapy with FAK inhibitor.
• •Woman who are pregnant or breastfeeding.
• •Have received a live vaccine or live-attenuated vaccine within 30 days prior to study drug.
• •Is currently or has participated in another investigational study within 4 weeks prior to receiving study drug.
• •History or current use of immunosuppressive medications within 7 days prior to study medications.
• •Has a known additional malignancy that is progressing or has required active treatment within the past 2 years or that is expected to require active treatment within two years.
• •Has active autoimmune disease that has required systemic treatment in the past 2 years.
• •Has a history of (non-infectious) pneumonitis/interstitial lung disease or current pneumonitis.
• •Has an active infection requiring systemic therapy.
• •Infection with HIV or hepatitis B or C.
• •Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Known allergy or hypersensitivity to the study drugs.
• •Received any growth factors including, but not limited to, granulocyte-colony stimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of study drug administration.
• •Has history of any organ transplant, including corneal transplants.